510(k) · Radiology

Transpara 1.7.2

by ScreenPoint Medical B.V.

Transpara 1.7.2 is an AI-enabled medical device from ScreenPoint Medical B.V. that the U.S. FDA cleared through 510(k) K221347 on August 3, 2022. Its lead review panel is Radiology and its primary product code is QDQ (Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer).

See also FDA-cleared AI radiology devices in 2022, all FDA AI clearances in 2022, top radiology AI devices.

Key facts

Submission numberK221347
Pathway510(k)
Date of final decision
Company (FDA list)ScreenPoint Medical B.V.
Lead review panelRadiology
Primary product codeQDQ — Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer
Applicant (openFDA)Screenpoint Medical B.V.
Applicant locationNijmegen, NL
Device classClass 2
Regulation number21 CFR 892.2090
Decision codeSESE
Submission typeTraditional

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. Transpara 1.7.2 went through this pathway (K221347).

openFDA lists it as a Class 2 device under 21 CFR 892.2090. Class II devices are moderate risk and are subject to general and special controls.

Product code QDQ covers 36 devices on the FDA AI list. By decision date, this device is #15 of 36 under that code. ScreenPoint Medical B.V. has 7 AI-enabled devices on the list, and the Radiology panel accounts for 1,230 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code QDQ)

More from ScreenPoint Medical B.V.